Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Kintor Pharmaceuticals

Request full access

A Pharmaceutical research company

Suzhou Shi, ChinaFounded 2009Biotech & Life Sciences

About Suzhou Kintor Pharmaceuticals

Established in Suzhou in 2009 by Dr. Youzhi Tong, Kintor Pharmaceuticals is a clinical-stage biotechnology company focused on the research and development of novel therapeutics. Dr. Tong, the company's founder and CEO, has over 25 years of experience in new drug R&D and previously served as a vice-president at Angion Biomedica Corp. in the United States. The company is publicly traded on the Hong Kong Stock Exchange under the ticker 9939.HK.

Kintor's business strategy centers on developing and commercializing a diverse pipeline of small-molecule drugs and biological therapeutics. The company targets androgen receptor (AR)-related diseases and other conditions with significant unmet medical needs, primarily in the fields of dermatology and oncology. Its portfolio includes seven drug candidates in Phase I-III clinical trials across China and other countries. Recently, the company has shifted its focus towards the commercialization of cosmetic products to generate revenue while continuing clinical trials for prescription drug applications.

The company's product pipeline features several key candidates. GT20029 is a topical androgen receptor degrader developed using Kintor's proprietary PROTAC platform for the treatment of androgenetic alopecia (AGA) and acne. Phase II trials in China for male AGA have met their primary endpoints, demonstrating efficacy and safety. Another key asset is KX-826 (pyrilutamide), a topical AR antagonist also being investigated for AGA and acne. The company has begun selling an over-the-counter cosmetic version of KX-826 called Koshiné. Proxalutamide (GT-0918) is a nonsteroidal antiandrogen that was explored for COVID-19 and is also in late-stage development for metastatic prostate cancer. However, a Phase III trial for prostate cancer as a monotherapy did not meet its primary endpoint. The pipeline also includes GT1708F, a Hedgehog/SMO inhibitor for idiopathic pulmonary fibrosis (IPF) and hematologic malignancies, which has received approval for a Phase II trial in China for IPF.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
16.0/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jan 2018 $44M $176M CCB International · Oriza Holdings · Green Pine Capital —
EARLY VCOther financing Jul 2015 $10M $40M Highlight Capital —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Kintor Pharmaceuticals website traffic

Latest recorded traffic for Suzhou Kintor Pharmaceuticals is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Kintor Pharmaceuticals in the Suzhou Shi ecosystem

Live from Dealroom

The Suzhou Kintor Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Highlight Capital

Series B and later3 investors entered at this stage

  • CCB International
  • Oriza Holdings
  • Green Pine Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Kintor Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Kintor Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.